Stephen Anthony
Sumitomo Pharma America, Inc. · Evergreen Hematology & Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Stephen Anthony as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:13 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03969420 · Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination TherapySumitomo Pharma America, Inc. · terminated · Acute Myeloid Leukemia (AML) · study director
- Ph1/Ph2NCT03593915 · A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDSSumitomo Pharma America, Inc. · terminated · Myelodysplastic Syndromes (MDS) · study director
- Ph1NCT03298984 · Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).Sumitomo Pharma America, Inc. · completed · Acute Myeloid Leukemia · study director
- Ph2NCT02520011 · Alvocidib Biomarker-driven Phase 2 AML StudySumitomo Pharma America, Inc. · terminated · Acute Myeloid Leukemia · study director
- N/ANCT01919749 · A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast CancerTranslational Drug Development · completed · Metastatic Breast Cancer · principal investigator
- Ph1NCT00455052 · A Study of Intravenous XMT-1001 in Patients With Advanced Solid TumorsMersana Therapeutics · completed · Small Cell Lung Cancer, Non-small Cell Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:13 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:13 UTC. The ranking covers the 200 most relevant of 41 PubMed records, and a shared surname and initials can bring in a namesake. All 41 on PubMed
- Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.N Engl J Med · 2015464 citationsRCR 12.7
- Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.J Clin Oncol · 2006416 citationsRCR 8.7
- Community reinforcement therapy for cocaine-dependent outpatients.Arch Gen Psychiatry · 2003135 citationsRCR 4.3
- Transition Intervention for Adolescents With Congenital Heart Disease.J Am Coll Cardiol · 2018128 citationsRCR 8.4
- Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.Eur J Cancer · 2012110 citationsRCR 2.7
- Patient-reported Symptoms of Tenosynovial Giant Cell Tumors.Clin Ther · 201693 citationsRCR 3.4
- 71 citationsRCR 1.5
- Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.Lancet Oncol · 202270 citationsRCR 4.3
- Phase 1 study of escalating-dose OncoGel (ReGel/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions.Anticancer Drugs · 200768 citationsRCR 1.9
- A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer.Breast Cancer Res Treat · 201468 citationsRCR 1.6